Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Should You Buy?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped up prior to trading on Monday . The stock had previously closed at $9.15, but opened at $9.79. Sysmex shares last traded at $9.80, with a volume of 2,851 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

Sysmex Stock Up 2.1%

The stock has a market cap of $6.26 billion, a P/E ratio of 26.18 and a beta of 1.07. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The stock’s 50-day moving average is $9.13 and its 200-day moving average is $9.05.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $877.92 million for the quarter, compared to the consensus estimate of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, research analysts anticipate that Sysmex Corporation ADR will post 0.42 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.